These findings reveal FABP4 as a crucial regulator of obesity‐related myometrial dysfunction, offering a potential target for therapeutic interventions to improve labor outcomes in obese pregnancies. Here, FABP4 is linked to obesity due to melanocortin 4 receptor deficiency.